HTI Halozyme Therapeutics

SAN DIEGO, May 2 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (AMEX:HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present at the following investment conferences during the month of May: * 2007 UBS Global Generic and Specialty Pharmaceuticals Conference being held at the Grand Hyatt New York Hotel on Wednesday, May 9, 2007 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time); and * Citigroup's 2007 Global Healthcare Conference to be held at the Hilton New York Hotel on Thursday, May 24, 2007 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). Interested parties can access a live audio webcast and accompanying slides of the UBS conference presentation and a live audio webcast and slides of the Citigroup conference presentation via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.halozyme.com/. Archived presentations will be available on the Web site for 30 days following the presentation date. About Halozyme Therapeutics, Inc. Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need. Halozyme Contact Investor Relations Contact David A. Ramsay Don Markley Chief Financial Officer Lippert/Heilshorn & Associates (858) 794-8881 (310) 691-7100 DATASOURCE: Halozyme Therapeutics, Inc. CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme Therapeutics, Inc., +1-858-794-8881, ; or Investor Relations, Don Markley of Lippert/Heilshorn & Associates, +1-310-691-7100, , for Halozyme Therapeutics, Inc. Web site: http://www.halozyme.com/

Copyright